Singapore: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Triamcinolone Acetonide Ointment USP, 0.5%, the generic version of Triamcinolone Acetonide Ointment USP, 0.5% of Perrigo New York, Inc.

According to IMS Health sales data for the 12 month period ending May 2016, the Triamcinolone Acetonide Ointment USP, 0.5% market1 achieved annual sales of approximately $4.4 million.

Glenmark's current portfolio consists of 116 products authorized for distribution in the US marketplace and 61 ANDA's pending approval with the USFDA.